Herman G. M. Westenberg
#165,945
Most Influential Person Now
Herman G. M. Westenberg's AcademicInfluence.com Rankings
Herman G. M. Westenbergbiology Degrees
Biology
#13447
World Rank
#16992
Historical Rank
Neuroscience
#2332
World Rank
#2396
Historical Rank
Download Badge
Biology
Herman G. M. Westenberg's Degrees
- PhD Neuroscience University of Amsterdam
- Masters Biomedical Engineering Delft University of Technology
Why Is Herman G. M. Westenberg Influential?
(Suggest an Edit or Addition)Herman G. M. Westenberg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. (2010) (619)
- Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. (2006) (461)
- The bovine protein alpha-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids, and in vulnerable subjects raises brain serotonin activity, reduces cortisol concentration, and improves mood under stress. (2000) (281)
- Partitioning the Heritability of Tourette Syndrome and Obsessive Compulsive Disorder Reveals Differences in Genetic Architecture (2013) (280)
- Dysfunctional Reward Circuitry in Obsessive-Compulsive Disorder (2011) (275)
- Genome-wide association study of obsessive-compulsive disorder (2013) (256)
- The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. (2004) (252)
- Altered pain processing in veterans with posttraumatic stress disorder. (2007) (223)
- Glutamate and anxiety (2004) (215)
- Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors (2000) (207)
- Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder (2004) (194)
- A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. (2004) (183)
- The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. (1994) (174)
- Autonomic and Neuroendocrine Responses to a Psychosocial Stressor in Adults with Autistic Spectrum Disorder (2006) (169)
- Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder (2007) (166)
- Reduced GABAA benzodiazepine receptor binding in veterans with post-traumatic stress disorder (2008) (159)
- Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. (1987) (155)
- Thinner prefrontal cortex in veterans with posttraumatic stress disorder (2008) (155)
- Neurobiology of Obsessive-Compulsive Disorder: Serotonin and Beyond (2007) (140)
- Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine (1994) (139)
- Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with Attention Deficit Hyperactivity Disorder (2003) (135)
- Spatial working memory deficits in obsessive compulsive disorder are associated with excessive engagement of the medial frontal cortex (2003) (133)
- Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. (1998) (131)
- Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients (2000) (129)
- Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder (2013) (129)
- Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. (2015) (123)
- Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder. (2004) (120)
- A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder (2003) (118)
- IMPACT OF IMPAIRED SLEEP ON THE DEVELOPMENT OF PTSD SYMPTOMS IN COMBAT VETERANS: A PROSPECTIVE LONGITUDINAL COHORT STUDY (2013) (117)
- Reduced sensitivity in the recognition of anger and disgust in social anxiety disorder (2006) (115)
- Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. (2002) (114)
- Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor (1992) (113)
- Neural correlates of associative learning and memory in veterans with posttraumatic stress disorder. (2008) (112)
- Female hormones affect symptom severity in obsessive–compulsive disorder (2006) (112)
- Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients (1996) (106)
- Leukocyte glucocorticoid receptor expression and immunoregulation in veterans with and without post-traumatic stress disorder (2007) (105)
- Cholecystokinin in anxiety (1996) (105)
- Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. (2008) (104)
- Increased Serotonin and Dopamine Transporter Binding in Psychotropic Medication–Naïve Patients with Generalized Social Anxiety Disorder Shown by 123I-β-(4-Iodophenyl)-Tropane SPECT (2008) (101)
- A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. (2004) (101)
- Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder (1990) (99)
- Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive–compulsive disorder: a meta-analysis of randomized controlled treatment trials (2006) (98)
- Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. (1987) (95)
- Use of factor analysis to detect potential phenotypes in obsessive-compulsive disorder (2004) (94)
- Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. (2012) (92)
- Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. (1988) (90)
- Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: An in vivo microdialysis study (2005) (89)
- Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. (1997) (88)
- Sympathetic activity and hypothalamo-pituitary–adrenal axis activity during sleep in post-traumatic stress disorder: A study assessing polysomnography with simultaneous blood sampling (2013) (88)
- The effect of stress on the dexamethasone suppression test (1985) (82)
- Attention and cognition in patients with obsessive–compulsive disorder (2007) (81)
- Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive–compulsive disorder in males (2006) (78)
- Oxytocin in obsessive compulsive disorder (1992) (78)
- Deep Brain Stimulation Reveals a Dissociation of Consummatory and Motivated Behaviour in the Medial and Lateral Nucleus Accumbens Shell of the Rat (2012) (77)
- Decreased TNF-α and NK activity in obsessive-compulsive disorder (2004) (77)
- Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder. (2006) (75)
- Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin (2005) (74)
- Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. (2008) (71)
- Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. (2002) (71)
- A Double-Blind Placebo-Controlled Study of Controlled Release Fluvoxamine for the Treatment of Generalized Social Anxiety Disorder (2004) (71)
- Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks (1997) (69)
- Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review (2006) (68)
- Differences in the response to the combined DEX-CRH test between PTSD patients with and without co-morbid depressive disorder (2008) (66)
- Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. (2011) (66)
- L-5-hydroxytryptophan in the treatment of anxiety disorders. (1985) (66)
- Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. (2009) (66)
- The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder (1996) (65)
- Sexual pleasure in women with obsessive-compulsive disorder? (2006) (62)
- Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. (2005) (62)
- Extracellular 5‐Hydroxytryptamine in Median Raphe Nucleus of the Conscious Rat Is Decreased by Nanomolar Concentrations of 8‐Hydroxy‐2‐(Di‐n‐Propylamino)tetralin and Is Sensitive to Tetrodotoxin (1994) (62)
- Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. (1997) (62)
- Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. (2007) (62)
- Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine (2004) (61)
- Symptom Dimensions in Obsessive-Compulsive Disorder: Factor Analysis on a Clinician-Rated Scale and a Self-Report Measure (2004) (61)
- Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740 (2005) (61)
- Long-Term Behavioral Changes After Cessation of Chronic Antidepressant Treatment in Olfactory Bulbectomized Rats (2007) (61)
- Advances in the neurobiology of schizophrenia (1995) (60)
- Advances in the neurobiology of anxiety disorders (1996) (60)
- Postsynaptic serotonergic activity in depressive patients: Evaluation of the neuroendocrine strategy (1982) (59)
- Placebo-controlled studies in depression: necessary, ethical and feasible (2003) (59)
- Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients (1994) (57)
- Wireless implantable micro-stimulation device for high frequency bilateral deep brain stimulation in freely moving mice (2012) (56)
- Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia (1995) (56)
- Effect of a pharmacological intervention on quality of life in patients with obsessive–compulsive disorder (2003) (55)
- [Body dysmorphic disorder in 3-8% of patients in outpatient dermatology and plastic surgery clinics]. (2006) (54)
- Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine (2005) (54)
- Postsynaptic 5-HT1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe. (1997) (54)
- Assessment of DSM-IV personality disorders in obsessive-compulsive disorder: comparison of clinical diagnosis, self-report questionnaire, and semi-structured interview. (2003) (51)
- A score for predicting response to pharmacotherapy in obsessive–compulsive disorder (2003) (51)
- Decreased nocturnal growth hormone secretion and sleep fragmentation in combat-related posttraumatic stress disorder; potential predictors of impaired memory consolidation (2011) (51)
- Plasma monoamine metabolites and aggression: two studies of normal and oppositional defiant disorder children (1999) (50)
- Developments in the drug treatment of panic disorder: what is the place of the selective serotonin reuptake inhibitors? (1996) (49)
- Noradrenaline concentrations and electrocardiographic abnormalities after aneurysmal subarachnoid haemorrhage. (1995) (49)
- Neuroleptic malignant syndrome: Successful treatment with bromocriptine (1985) (49)
- Effects of dietary tryptophan variations on extracellular serotonin in the dorsal hippocampus of rats (2004) (48)
- Lower Baseline Plasma Cortisol and Prolactin together with Increased Body Temperature and Higher mCPP-Induced Cortisol Responses in Men with Pedophilia (2001) (47)
- Attachment representations in Dutch veterans with and without deployment-related PTSD (2009) (47)
- Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive–compulsive disorder and controls (1998) (47)
- Serotonergic functioning in children with oppositional defiant disorder: a sumatriptan challenge study (2002) (47)
- Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder (1998) (44)
- Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine (1998) (43)
- Chronic treatment with fluvoxamine by osmotic minipumps fails to induce persistent functional changes in central 5-HT1A and 5-HT1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats (1995) (43)
- Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT1B autoreceptors: a microdialysis study in knockout mice (2002) (42)
- Dose-related effect of methylphenidate on stopping and changing in children with attention-deficit/hyperactivity disorder (2006) (42)
- Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study (2010) (42)
- The nature of social anxiety disorder. (1998) (41)
- Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. (2005) (40)
- Kinetics of l-5-hydroxytryptophan in healthy subjects (1982) (39)
- The Effect of Olanzapine Treatment on Monoamine Metabolite Concentrations in the Cerebrospinal Fluid of Schizophrenic Patients (2001) (39)
- A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. (1996) (39)
- Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. (2003) (38)
- Precuneal activity during encoding in veterans with posttraumatic stress disorder. (2008) (37)
- Disgust affects TNF-α, IL-6 and noradrenalin levels in patients with obsessive–compulsive disorder (2010) (37)
- Behavioral biochemical and neuroendocrine concomitants of lactate-induced panic anxiety (1989) (35)
- Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. (2004) (35)
- Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls (1997) (34)
- Signaling pathways involved in Ca2+- and Pb2+-induced vesicular catecholamine release from rat PC12 cells (2002) (34)
- The adequacy of pharmacotherapy in outpatients with obsessive–compulsive disorder (2002) (33)
- Genome-wide association study of obsessive-compulsive disorder (2013) (33)
- Anhedonia, suicide ideation and dexamethasone nonsuppression in depressed patients. (1990) (33)
- Overview of panic and social anxiety disorders. (2004) (33)
- Role of 5-HT1B receptors in the regulation of extracellular serotonin and dopamine in the dorsal striatum of mice. (2003) (32)
- Saccadic abnormalities in psychotropic-naive obsessive–compulsive disorder without co-morbidity (2006) (32)
- Lipopolysaccharide-induced cytokine production in obsessive–compulsive disorder and generalized social anxiety disorder (2010) (31)
- Serotonin function in panic disorder: effect of 1–5-hydroxytryptophan in patients and controls (2004) (31)
- Pedophilia is accompanied by increased plasma concentrations of catecholamines, in particular epinephrine (2001) (31)
- Increasing Dopaminergic Activity: Effects of L-Dopa and Bromocriptine on Human Sensory Gating (2004) (30)
- The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice. (2002) (30)
- Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. (2008) (29)
- Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response. (1996) (29)
- Stimulation of the pituitary-adrenal axis with a low dose [Arg8]-vasopressin in depressed patients and healthy subjects (1992) (29)
- Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder (1996) (28)
- Mirtazapine in social anxiety disorder: a pilot study (2002) (28)
- MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine (1993) (27)
- Endocrine and cardiovascular responses to a series of graded physical and psychological stress stimuli in healthy volunteers (1995) (27)
- 5-Hydroxytryptamine release in dorsal hippocampus of freely moving rats: Modulation by pindolol (1994) (27)
- Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. (2005) (26)
- Serotonin-influencing drugs in the treatment of panic disorder. (1989) (26)
- Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine (1995) (26)
- New findings in the treatment of panic disorder. (1993) (26)
- The dexamethasone and cortisol suppression test in depression: β-endorphin as a useful marker (1987) (25)
- Pharmacotherapeutic Treatment of Nightmares and Insomnia in Posttraumatic Stress Disorder (2006) (25)
- The effects of A 5-HT1A receptor agonist and antagonist on the 5-hydroxytryptamine release in the central nucleus of the amygdala: a microdialysis study with flesinoxan and WAY 100635 (1997) (24)
- Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive–compulsive disorder: possible mechanisms and implications for clinical care (2003) (24)
- Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade (2003) (23)
- No effects of l-dopa and bromocriptine on psychophysiological parameters of human selective attention (2006) (23)
- An evaluation of the effect of NAS-181, a new selective 5-HT1B receptor antagonist, on extracellular 5-HT levels in rat frontal cortex (2003) (23)
- Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms (2009) (23)
- Sensory gating and sensorimotor gating in medication-free obsessive-compulsive disorder patients (2010) (22)
- Neuroendocrine and immune responses to a cognitive stress challenge in veterans with and without PTSD (2012) (22)
- Characteristics of patients with social phobia and their treatment in specialized clinics for anxiety disorders in the Netherlands. (2001) (22)
- Recent Advances in Understanding and Treating Social Anxiety Disorder (2009) (22)
- Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. (2009) (21)
- (Des-tyrosine1)-gamma-endorphin in schizophrenia: Clinical, biochemical, and hormonal aspects (1981) (21)
- The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients (1997) (21)
- Obstructive sleep apnea in combat-related posttraumatic stress disorder: a controlled polysomnography study (2011) (21)
- Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder (2006) (21)
- Marked inbred mouse strain difference in the expression of quinpirole induced compulsive like behavior based on behavioral pattern analysis (2012) (20)
- On the significance of cholecystokinin receptors in panic disorder (1994) (20)
- Facing the challenge of social anxiety disorder (1999) (19)
- Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder (2012) (18)
- Pharmacokinetics of clomipramine in depressive patients (1981) (18)
- Effect of the cholecystokinin-B receptor antagonist L-365,260 on lactate-induced panic attacks in panic disorder patients (1996) (18)
- Clinical, biochemical, and hormonal aspects of treatment with des-tyr1-gamma-endorphin in schizophrenia (1984) (17)
- Remoxipride in schizophrenia (1986) (17)
- Fluvoxamine in the treatment of menstrually related mood disorders (2005) (17)
- d-Cycloserine Addition to Exposure Sessions in the Treatment of Patients With Obsessive-Compulsive Disorder (2017) (17)
- A comparative study on the antipsychotic properties of desenkephalin‐γ‐endorphin and ceruletide in schizophrenic patients (1986) (16)
- Clinical predictors of drug response in obsessive-compulsive disorder (2002) (15)
- Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats. (2007) (15)
- Clinical and Biochemical Effects of Selective Serotonin-Uptake Inhibitors in Anxiety Disorders (1988) (15)
- Do panic attacks reflect an abnormality in serotonin receptor subtypes? (1991) (14)
- Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). (1995) (14)
- Effects of quetiapine on cognitive functioning in obsessive–compulsive disorder (2007) (14)
- Immunoglobulin production in vitro in major depression: A pilot study on the modulating action of endogenous cortisol (1995) (13)
- Recent advances in the psychopharmacology of social phobia (1994) (13)
- The bovine protein a-lactalbumin increases the plasma ratio of tryptophan to the other large neutral amino acids , and in vulnerable subjects raises brain serotonin activity , reduces cortisol concentration , and improves mood under stress 1 – 3 C (2015) (13)
- A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. (2003) (13)
- Pentagastrin has panic-inducing properties in obsessive compulsive disorder (1996) (13)
- Inhibition of the pituitary-adrenal axis with dexamethasone and cortisol in depressed patients and healthy subjects: A dose-response study (1993) (12)
- Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls (2004) (12)
- Effect of the selective serotonin re-uptake inhibitor fluvoxamine on CCK-4 induced panic attacks (1995) (11)
- The MSH/ACTH analog ORG 2766 in anxiety disorders (1992) (10)
- L‐365,260, A CCKB ANTAGONIST, BLOCKS CCK‐4‐PANIC IN PANIC DISORDER (1992) (10)
- Psychopharmacology of anxiety disorders: on the role of serotonin in the treatment of anxiety states and phobic disorders. (1987) (10)
- Serotonergic function and late luteal phase dysphoric disorder (2005) (10)
- A double‐blind comparative study of remoxipride and haloperidol in acute schizophrenia. (1990) (9)
- MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients A preliminary report (1996) (9)
- FLESINOXAN, A SELECTIVE 5‐HT1A AGONIST, IN THE TREATMENT OF PANIC DISORDER. (1992) (8)
- Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder (1996) (8)
- Recent developments in the psychopharmacology of social phobia (1993) (8)
- Serotonin in Anxiety and Related Disorders (1993) (7)
- Treatment of non-fluctuating progressive dystonia: a neuropharmacological approach. (1984) (7)
- A DOUBLE BLIND COMPARATIVE STUDY OF FLUVOXAMINE AND BROFAROMINE IN PANIC DISORDER. (1992) (7)
- Clinical effects of venlafaxine in social phobia (1998) (7)
- [Sleep disturbances in post-traumatic stress disorder. An overview of the literature]. (2007) (6)
- Selective monoamine uptake inhibitors and a serotonin antagonist in the treatment of panic disorder. (1989) (6)
- Imaging trauma in vivo: GABAA benzodiazepine receptor binding (2008) (6)
- Paroxetine augmentation in patients with generalised social anxiety disorder, non‐responsive to mirtazapine or placebo (2011) (6)
- Remoxipride in Adolescents with Tourette's Syndrome : An Open Pilot Study (1995) (5)
- Letter Hormone response to 5-HTP: a reply (1984) (5)
- Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients (2005) (5)
- P.5.032 Clinical effects of buspirone in social phobia, a double-blind placebo controlled study (1996) (5)
- SINGLE BLIND DOSE RESPONSE‐STUDY WITH CHOLECYSTOKININ (CCK‐4) IN PANIC DISORDER PATIENTS. (1992) (5)
- MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients (1996) (5)
- Remoxipride, a novel atypical neuroleptic, in the treatment of schizophrenia. (1987) (4)
- Neuroimaging of Pain Perception in Dutch Veterans With and Without Posttraumatic Stress Disorder: Preliminary Results (2006) (4)
- Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia. (2002) (4)
- Critical notes on the locus coeruleus hypothesis of panic disorder (1993) (4)
- Reply to Joseph et al. (1984) (4)
- Biological dissection of anxiety disorders (1995) (4)
- The efficacy of a reversible MAO-A-inhibitor brofaromine, in panic disorder and social phobia: behavioural and biochemical results (1991) (4)
- Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol. (1990) (4)
- Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD (2016) (4)
- Pindolol does not augment the panicolytic effects of fluvoxamine in panic disorder patients (1998) (3)
- The ACTH (4-9) analog ORG 2766 in panic disorder: a preliminary study. (1989) (3)
- Stimulation of the pituitary-adrenal system with graded doses of CRH and low dose vasopressin infusion in depressed patients and healthy subjects: a pilot study (1993) (3)
- A double blind comparison of venlafaxine and paroxetine in obsessive compulsive disorder (2002) (3)
- Depression and some biological markers (1988) (3)
- A decade of biological psychiatric research on OCD (I): introduction and treatment-studies (1993) (3)
- Focus on psychiatry : antidepressants, selectivity or multiplicity (2001) (3)
- P.3.21 Double-blind, randomized, placebo-controlled addition of quetiapine in non-refractory OCD patients (2007) (3)
- Non-drug treatment for social anxiety disorder (1999) (3)
- P.1.b.014 Deep brain stimulation of the nucleus accumbens for therapy-refractory obsessive-compulsive disorder (2010) (3)
- A DOUBLE BLIND PLACEBO CONTROLLED STUDY OF FLUVOXAMINE IN SOCIAL PHOBIA. (1992) (3)
- EVIDENCE OF ENHANCED SENSITIVITY FOR PENTAGASTRIN IN PANIC DISORDER PATIENTS (1993) (3)
- Biological Aspects of Panic Anxiety (1990) (3)
- Neuropeptides and anxiety disorders (1992) (2)
- Panic Disorder—a Condition for Life? Treatment Issues (1997) (2)
- The prediction of response in the anxiety disorders (1996) (2)
- O-24-5 Developments in the drug treatment of panic disorder (1996) (2)
- A case of venlafaxine-induced inhibition of T-lymphocyte proliferation (2002) (2)
- The clinical significance of atypical antipsychotics (1991) (2)
- The effects of haloperidol on the EEG spectrum (2004) (2)
- P.1.e.025 Dysfunctional reward circuitry in obsessive-compulsive disorder (2010) (2)
- Obsessive-compulsive disorder revisited from a treatment perspective. (2007) (2)
- Basic mechanisms of panic and depression: Are they separate? (1998) (2)
- Changes in benzodiazepine receptor binding in Dutch veterans with posttraumatic stress disorder assessed with [C-11]-flumazenil and PET (2005) (2)
- Effects of Challenge with meta-chlorophenylpiperazine (mcpp) at Behavior and Cerebral Blood Flow in Obsessive Compulsive Disorder (1996) (2)
- A double blind switch study of venlafaxine and paroxetine in obsessive compulsive disorder (2002) (1)
- Pharmacological treatment of OCD (2008) (1)
- P-6-2 Single photon emission computed tomography (HMPAO-SPECT) in obsessive compulsive disorder, after symptom provocation with m-chlorophenylpiperazine (1995) (1)
- Significance of CCK-B receptors in the neurobiology of panic disorder (1994) (1)
- Neurobiology of anxiety disorders: Focus on neuroimaging (2000) (1)
- L-365,260, a CKKB receptor antagonist, blocks CCK-4-panic disorder (1992) (1)
- Effect of the cholecystokinin B receptor antagonist L-365-260 on lactate induced panic attacks (1994) (1)
- Developments in the Drug Treatment of Panic Disorder (1996) (1)
- Brofaromine versus fluvoxamine in panic disorder (1994) (1)
- Reduced efficacy of the spatial working memory system in obsessive compulsive disorder (2001) (1)
- Pharmacological treatment of social phobia; recent developments (1993) (1)
- RISPERIDONE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIA: A DOUBLE BLIND COMPARATIVE STUDY WITH HALOPERIDOL. (1992) (1)
- [Negative symptoms and schizophrenia. A concise review of clinical and pharmacotherapeutic data]. (1989) (1)
- Differential involvement of 5-HT in anxiety states (1992) (1)
- S.20.04 Challenge studies in obsessive-compulsive disorder; a key to the pathogenesis? (1997) (1)
- [Diagnostic aspects of anxiety disorders]. (1990) (0)
- Moving the brain: Neuroimaging motivational changes of deep brain stimulation in obsessive- compulsive disorder (2013) (0)
- Sleeping disorder in posttraumatic stress disorder (2004) (0)
- Behavioural effects of rapid i.v. challenge with meta-chlorophenylpiperazine (0.1 mg/kg) in patients with panic disorder and controls (1999) (0)
- Treatment options in social phobia (1998) (0)
- P.3.018 Decreased TNF-α, IL-6, and NK activity in obsessive-compulsive disorder (2003) (0)
- 123I Beta-CIT SPECT of dopamine and serotonine transporters in obsessive compulsive disorder (2001) (0)
- Changes of lactate concentrations in hippocampus and caudate putamen after various stresses in freely moving rats (1991) (0)
- Addition of behaviour therapy enhances treatment outcome of patients with obsessive-compulsive disorder already responding to medication (2002) (0)
- CONTINUOUS ON LINE MEASUREMENT OF LACTATE AFTER MILD STRESSORS AND ANXIOLYTICS IN RAT HIPPOCAMPUS AND PUTAMEN. (1992) (0)
- Neurobiological parameters of PTSD in military and veterans with PTSD (2001) (0)
- P.3.015 Sumatriptan (5-HT1D receptor agonist) does not provoke symptoms in obsessive compulsive disorder (1997) (0)
- CHAPTER 4 Interactions between serotonin and dopamine in the striatum are not mediated by striatal 5-HT 1 B receptors (2002) (0)
- The Effects of Ketamine and Haloperidol on Human Selective Attention (2008) (0)
- Neurobiology of panic disorder (1998) (0)
- P.3.023 A double-blind, placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder (2003) (0)
- The role of serotonin and cholecystokinin in panic disorder (1993) (0)
- NO EVIDENCE FOR ANTICOMPULSIVE ACTION OF OXYTOCIN. (1992) (0)
- S.07.05 Deep brain stimulation of the ventral striatum affects consummatory and motivated behaviour in a location-specific manner (2011) (0)
- The role of the ‘central’ cholecystokinin-B receptor in panic disorder (1996) (0)
- Contents, Vol. 22, Supplement 1, 1989 (1989) (0)
- Treatment of panic disorder: Algorithms for pharmacotherapy. (1997) (0)
- 14-35 The prediction of nonresponse to drug therapy in social phobia (1997) (0)
- Exits and their putative significance in psychiatry (1986) (0)
- Dexamethasone non-suppression as a clinical variable in identifying a subgroup of depressed patients (1988) (0)
- PHARMACOKINETIC AND CLINICAL PROPERTIES OF A RACLOPRIDE DEPOT PREPARATION IN SCHIZOPHRENIC PATIENTS. (1992) (0)
- [Inadequate pharmacotherapy in patients with obsessive-compulsive disorder]. (2001) (0)
- P.3.017 A double-blind, randomized, placebo-controlled trial of quetiapine augmentation in patients with obsessive-compulsive disorder resistant to serotonin reuptake inhibitors (2003) (0)
- The nature of social anxiety disorder. Discussion (1998) (0)
- S-18-5 New alternatives for the pharmacotherapy of anxiety disorders (1995) (0)
- Depressive symptomatology, hospitalisation and life events (1986) (0)
- Serotonergic and Cholecystokininergic Challenges in Panic Disorder (1996) (0)
- OXYTOCIN AND COGNITIVE PROCESSES IN HEALTHY SUBJECTS AND OBSESSIVE COMPULSIVE DISORDER. (1992) (0)
- P.1.037 Clinical and neuroendocrine response to fluvoxamine treatment in impulsive borderline personality disorder (1996) (0)
- Biological markers in depression (1986) (0)
- Spatial working memory in obsessive compulsive disorder: A three-dimensional functional magnetic resonance imaging study (1999) (0)
- Anhedonia and suicidal ideation characterize a subgroup of depressed patients (1984) (0)
- Suicidal ideation, anhedonia and some biological markers in depression (1985) (0)
- P.6.085 Synergistic effects of quetiapine in combination with fluvoxamine on dopamine release in rat prefrontal cortex (2003) (0)
- [The role of drugs in the treatment of obsessive-compulsive disorders]. (1990) (0)
- S.15.05 Impulsivity and compulsivity: translational .ndings on the role of dopamine (2006) (0)
- Changes in benzodiazepine receptor binding in Dutch veterans with posttraumatic stress disorder (2006) (0)
- A subgroup of depressive patients is identified by anhedonia, suicidal ideation and dexamethasone nonsuppression: Recent advances in psychiatric treatment: An update for clinical practice (1987) (0)
- 431. The effect of the CCK-B receptor antagonist CI-988 on CCK-4 induced panic attacks (1996) (0)
- 5‐HT RELEASE IN DORSAL HIPPOCAMPUS OF FREELY MOVING RATS. (1992) (0)
- [Biological determinants of schizophrenic psychoses]. (1984) (0)
- The neurobiology of anxiety disorders (1998) (0)
- Temperament and character inventory: Predictor of pharmacological treatment response in obsessive compulsive disorder? (2001) (0)
- Letter to the editor (1992) (0)
- Short communication Dose-related effect of methylphenidate on stopping and changing in children with attention-deficit/hyperactivity disorder (2006) (0)
- A decade of biological-psychiatric research in OCD (II): challenge-studies and neuroanatomical substrate (1993) (0)
- P.2.009 Compulsive behaviour in mice during daily scheduled food availability mimics ethological measures of OCD rituals (2011) (0)
- P-5-18 Heart rate and MHPG as predictors of nonresponse to drug therapy in panic disorder (1995) (0)
- Possible connections between biological markers and depressive symptoms (1987) (0)
- 5‐HT FUNCTION IN OBSESSIVE COMPULSIVE DISORDER, A TREATMENT STUDY WITH FLUVOXAMINE AND A CHALLENGE WITH 5‐HTP. (1992) (0)
- Life events as factors in the onset of depression and anxiety disorders : Method and diagnosis (1988) (0)
- The role of serotonin in the treatment of anxiety disorders (1990) (0)
- Adequacy of pharmacotherapy in obsessive compulsive disorder: Data on 200 outpatients (2001) (0)
- Sleep Disturbances in Posttraumatic Stress Disorder, An Overview of Literature: (517322011-520) (2007) (0)
- Suicidal ideation as research marker in depression (1985) (0)
- Effect of antidepressants on quality of life in obsessive-compulsive disorder (2002) (0)
- P.3.022 The efficacy of mirtazapine in socialanxiety disorder: A double-blind placebo controlled study with adjunctive paroxetime in nonresponders to treatment (2004) (0)
- S-9-2 Panic disorder and the serotonin system (1995) (0)
- Antidepressants: selectivity and multiplicity (2001) (0)
- LACK OF ANXIOLYTIC ACTION OF THE MSH/ACTH ANALOG ORG2766. (1992) (0)
- OCD quo vadis? The Cape Town consensus statement (2007) (0)
- Studying immunological and (neuro)endocrine parameters, in depressive patient, in relation to clinical response to treatment with antidepressants or placebo (2002) (0)
- Challenge Studies in Obsessive Compulsive Disorder: Recent Developments with Mcpp and Pentagastrin (1996) (0)
- Biological markers and depressive symptoms (1987) (0)
- P-2-41 Fluvoxamine induced change of 5 HT receptor sensitivity in impulsive borderline personality disorder (1995) (0)
- CONCEPTS OF ANXIETY: A HISTORICAL REFLECTION ON ANXIETY AND RELATED DISORDERS Published as: Glas, G. (1996), Concepts of anxiety: a historical reflection on anxiety and related disorders. In: (2010) (0)
- Downstream effects of traumatic stress: neuroendocrine alterations (2007) (0)
- Hormone response to 5-HTP: a reply. (1984) (0)
- P.5.034 The effects of meta-chlorophenylpiperazine at cerebral blood flow and behavior in Obsessive Compulsive Disorder (OCD). Is the cerebellum involved in OCD? (1996) (0)
- THE EFFICACY OF SELECTIVE SEROTONIN UPTAKE INHIBITORS IN THE TREATMENT OF PANIC DISORDER. (1992) (0)
- Clinical, neurobiological, pharmacological, and genetic issues of obsessive-compulsive disorder (2003) (0)
- Clinical characteristics of obsessive-compulsive disorder: A sample of 300 OCD-outpatients (2001) (0)
- Biological concepts of anxiety disorders (1997) (0)
- Some depressive patients are characterized by anhedonia, suicidal ideation and dexamethasone nonsuppression (1987) (0)
- S-23-3 Basic and clinical aspects of social phobia (1995) (0)
- S.22.03 Brain imaging and PTSD (2008) (0)
- Klinische, neurobiologische en genetische aspecten van dwangneurose (2003) (0)
- Poster Session 2: ORGANIC MENTAL DISORDERS AND MEMORY AND COGNITIVE DYSFUNCTIONS (2007) (0)
- 11-4 Heart rate and MHPG as predictors of nonresponse to drug therapy in panic disorder (1997) (0)
This paper list is powered by the following services:
